Management of cardiovascular risk in the light of current recommendations

1. Zimmet PZ, Magliano DJ, Herman WH et al. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2014; 2(1): 56–64. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(13)70112–8>.

2. Catapano AL, Graham I, De Backer G et al. Task Force Members. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37(39): 2999–3058.

3. Gæde P, Lund-Andersen H, Parving H-H et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358(6): 580–591. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0706245>.

4. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315–2381. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw106>.

5. Barry VW, Baruth M, Beets MW et al. Fitness vs. fatness on all-cause mortality: a meta-analysis. Prog Cardiovasc Dis 2014; 56(4): 382–390. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pcad.2013.09.002>.

6. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? a systematic review and meta-analysis. Ann InternMed 2013; 159(11): 758 –769. Dostupné z DOI: <http://dx.doi.org/10.7326/0003–4819–159–11–201312030–00008>.

7. Loomba R, Abraham M, Unalp A et al.Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56(3): 943–951. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.25772>.

8. [American Diabetes Association]. Standards of medical care in diabetes 2017. Diabetes Care 2017; 40(Supp 1): 1–142. Dostupné z WWW: <http://care.diabetesjournals.org/content/diacare/suppl/2016/12/15/40.Supplement_1.DC1/DC_40_S1_final.pdf>.

9. Shaw K, Gennat H, O’Rourke P et al. Exercise for overweight or obesity. Cochrane Database Syst Rev 2006;(4): CD003817.

10. [Look AHEAD Research Group]. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity (SilverSpring) 2014; 22(1): 5–13. Dostupné z DOI: <http://dx.doi.org/10.1002/oby.20662>.

11. Steven S, Hollingsworth KG, Al-Mrabeh A, et al. Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders. Diabetes Care 2016; 39(5): 808–815. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15–1942>.

12. Bantle JP, Wylie-Rosett J, Albright AL et al. [American Diabetes Association]. Nutrition recommendations and interventions for diabetes: a position statement of the ADA. Diabetes Care 2008; 31(Suppl 1): S61-S78. Dostupné z DOI: <http://dx.doi.org/10.2337/dc08-S061>. Erratum in Diabetes Care 2010; 33: 1911.

13. Rubino F, Nathan DM, Eckel RH et al. [Delegates of the 2nd Diabetes Surgery Summit]. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 2016; 39(6): 861–877. Dostupné z DOI: <http://dx.doi.org/10.2337/dc16–0236>.

14. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311(1):74–86. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2013.281361>.

15. Kwok CS, Pradhan A, Khan MA et al. Bariatric surgery and its impact on cardiovascular disease and mortality:a systematic review and meta-analysis. Int J Cardiol 2014; 173(1): 20–28. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2014.02.026>.

16. Estruch R, Ros E, Salas-Salvado´ J et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368(14): 1279–1290. <http://dx.doi.org/10.1056/NEJMoa1200303>.

17. [Physical Activity Guidelines Advisory Committee]. Physical Activity Guidelines Advisory Committee Report,2008. U.S.Department of Health and Human Services: Washington, DC 2008. Dostupné z WWW: <https://health.gov/paguidelines/report/pdf/CommitteeReport.pdf>.

18. Boulé NG, Haddad E, Kenny GP et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus. A meta-analysis of controlled clinical trials. JAMA 2001; 286(10): 1218–1227.

19. Chow CK, Jolly S, Rao-Melacini P et al. Association of diet,exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010; 121(6): 750 –758. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.109.891523>.

20. Kotseva K, Wood D, De Bacquer D et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from24 European countries. Eur J Prev Cardiol 2016; 23(6): 636–648. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487315569401>.

21. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903–1913.

22. [International Diabetes federation]. Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. International Diabetes Federation: 2012. ISBN 2–930229–43–8. Dostupné z WWW: <https://www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes>.

23. 23.. Mancia G, Facchetti R, Bombelli M et al. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatoryblood pressure. Hypertension 2006; 47(5): 846–853.

24. Emdin CA, Rahimi K, Neal B et al. Blood pressure lowering intype 2 diabetes: a systematic review and metaanalysis. JAMA 2015; 313(6): 603–615. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2014.18574>.

25. Anderson RJ, Bahn GD, Moritz TE et al. [VADT Study Group]. Blood pressure and cardiovascular disease riskin the Veterans Affairs Diabetes Trial. Diabetes Care 2011; 34(1): 34–38. Dostupné z DOI: <http://dx.doi.org/10.2337/dc10–1420>.

26. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of highblood pressure in adults: report from the panel members appointed to the Eighth Joint NationalCommittee (JNC 8). JAMA 2014; 311(5): 507–520. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2013.284427>. Erratum in JAMA 2014; 311(17): 1809.

27. Hansson L, Zanchetti A, Carruthers SG et al. [HOT Study Group]. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT)randomised trial. Lancet 1998; 351(9118): 1755–1762.

28. Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in peoplewith diabetes mellitus. Cochrane DatabaseSyst Rev 2013; (10): CD008277. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD008277.pub2.

29. McBrien K, Rabi DM, Campbell N, et al. Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2012; 172(17): 1296–1303. Dostupné z DOI:

30. Margolis KL, O’Connor PJ, Morgan TM et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes:the ACCORD randomized trial. Diabetes Care 2014; 37(6): 1721–1728. Dostupné z DOI: <http://dx.doi.org/10.2337/dc13–2334>.

31. 31.Patel A, MacMahon S, Chalmers J et al. [ADVANCE Collaborative Group]. Effects of afixed combination of perindopril and indapamide on macrovascular and microvascular outcomes inpatients with type 2 diabetes mellitus (theADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829–840.

32. Bangalore S, Fakheri R, Toklu B et al. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers:systematic review and meta-analysis of randomized trials [published correction appears in ]. BMJ 2016; 352: i438. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.i438>. Erratum in BMJ 2016; 352: i152.

33. Mihaylova B, Emberson J, Blackwell L et al.[Cholesterol Treatment Trialists’ Collaboration]. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380(9841): 581–590. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(12)60367–5>.

34. Di Angelantonio E, Sarwar N, Perry P et al. [Emerging Risk Factors Collaboration] Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302(18): 1993–2000. <http://dx.doi.org/10.1001/jama.2009.1619>.

35. Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-densitylipoprotein cholesterol in patients at high risk of cardiovascular disease: evidenceand guidance for management. Eur HeartJ 2011; 32(11): 1345–1361. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehr112>.

36. Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380(9841): 572–580. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(12)60312–2>. Erratum in Lancet 2012; 380(9841): 564.

37. Jorgensen AB, Frikke-Schmidt R, West AS et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013; 34(24): 1826–1833. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehs431>.

38. Waters DD, Ho JE, Boekholdt SM et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013; 61(2):148–152. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.09.042>. Erratum in J Am Coll Cardiol 2014; 64(18): 1970.

39. Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus: an abridged Cochranereview. Diabet Med 2014; 31(1): 2–14. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.12295. Erratum in Diabet Med 2014; 31(2): 249.

40. Navarese EP, Kolodziejczak M, Kereiakes DJ et al. Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review. Ann Intern Med 2016; 164(9): 600–607.Dostupné z DOI:

41. Lee M, Saver JL, Towfighi A et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis 2011; 217(2): 492–498. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2011.04.020>.

42. Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patientswith type 2 diabetes mellitus—a pooled meta-analysis of randomized placebocontrolled clinical trials. Int J Cardiol 2010; 141(2): 157–166. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2008.11.211>.

43. Allemann S, Diem P, Egger M et al. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: metaanalysis of randomised con trolled trials. Curr Med Res Opin 2006; 22(3): 617–623.

44. Nathan DM, Genuth S, Lachin J et al. [The Diabetes Control and Complications Trial Research Group]. The effect of intensive treatmentof diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977–986.

45. [UK Prospective Diabetes Study (UKPDS) Group]. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854–865. Erratum in Lancet 1998; 352(9139): 1558.

46. Green JB, Bethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373(3): 232–242. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1501352>. Erratum in Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373(6): 586. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMx150029>.

47. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.

48. [Antiplatelet Trialists’ Collaboration]. Collaborative overview of randomised trialsof antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.BMJ 1994; 308(6921): 81–106. Erratum in BMJ 1994; 308(6943): 1540.